GDP366

产品说明书

Print
Chemical Structure| 501698-03-9 同义名 : -
CAS号 : 501698-03-9
货号 : A1155010
分子式 : C20H17N5OS
纯度 : 99%+
分子量 : 375.45
MDL号 : MFCD31544386
存储条件：

Pure form Keep in dark place, sealed in dry, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
描述 Survivin plays a pivotal role in not only cell survival but also cell cycle progression. Op18 (stathmin) is an oncoprotein that regulates microtubule stabilization. Both survivin and Op18 have been proposed as therapeutic targets for cancer. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. HCT116 cells were exposed to escalating concentrations of GDP366 for 48 hours or a fixed concentration (2.0 μM) of GDP366 for various durations, western blotting analysis revealed a dose- and time-dependent decrease of survivin and Op18, while the expression of p53 and p21 was remarkably increased in a dose- and time-dependent manner. Moreover, GDP366 inhibited the surviving clonogenic HCT116 cells in a dose-dependent manner, with an IC50 value of approximately 1.0 μM. In BALB/c mice inoculated with HCT116 cells, GDP366 at the dosage of 50 mg/kg, daily i.p., for 16 d potently inhibited the growth of HCT116 tumors. GDP366-treated tumors were significantly lower in weight than control tumors[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.32mL

2.66mL

1.33mL

26.63mL

5.33mL

2.66mL
参考文献

[1]Shi X, Wang D, Ding K, et al. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010;9(8):640-650